RuleDigest reads the Federal Register so you don't have to — a daily 3-minute briefing on regulatory changes that affect payment, reporting, and compliance operations.
Leads with the items that change deadlines, payment rates, or reporting duties — with the operational impact stated plainly.
Every item links straight to the Federal Register document. Verify anything in one click.
Written for compliance officers, healthcare IT leaders, and administrators — not lawyers billing by the hour.
July 6, 2026
1. CY 2027 Home Health PPS Rate Update – Proposed Rule - Deadline amp; Impact: Comment period open; final rule expected late 2026. Sets Medicare payment rates for all home health agencies effective January 2027. - Key Changes: Recalibrated case-mix weights, updated functional impairment levels, comorbidity subgroups, and LUPA thresholds. Includes temporary behavior adjustment proposal and home health palliative care services guidance. - Action Required: HH providers must review impact on labor costs, staffing models, and revenue projections. - URL: https://www.federalregister.gov/documents/2026/07/06/2026-13602/calendar-year-2027-home-health-prospective-payment-system-hh-pps-rate-update-requirements-for-the-hh
2. CMS-VA Data Matching Program – ACA Insurance Affordability Programs - Deadline amp; Impact: Privacy Act notice effective immediately; data sharing begins 30 days from publication unless agency objects. - Operational Change: CMS and VA will share eligibility data for Medicare, Medicaid, and marketplace insurance verification—affects patient enrollment workflows and compliance audits. - Action Required: IT teams verify secure data exchange protocols; compliance review HIPAA/Privacy Act obligations. - URL: https://www.federalregister.gov/documents/2026/07/06/2026-13572/privacy-act-of-1974-matching-program
3. 7-Hydroxymitragynine (Kratom) Controlled Substance Scheduling – RFI - Deadline amp; Impact: Public comment period open; HHS will submit input to DOJ for final scheduling decision. May affect pharmacy inventory, patient counseling, and DEA compliance programs. - Action Required: Facilities dispensing kratom products should monitor docket and prepare for potential Schedule I classification. - URL: https://www.federalregister.gov/documents/2026/07/06/2026-13608/temporary-placement-of-7-hydroxymitragynine-above-a-specified-threshold-in-schedule-i-request-for
34 NDAs Withdrawn (Endo Operations, et al.): FDA delisting approved drugs no longer marketed; update formulary and procurement systems. https://www.federalregister.gov/documents/2026/07/06/2026-13616/endo-operations-limited-et-al-withdrawal-of-approval-of-34-new-drug-applications
Vasopressin Determination: Clears generic ANDA pathway for vasopressin 0.9% injection; expect generic competition and cost reduction. https://www.federalregister.gov/documents/2026/07/06/2026-13492/determination-that-vasopressin-in-sodium-chloride-vasopressin-09-injection-50-units50-milliliters-1
Cassatt PSO Delisting: Patient Safety Organization voluntarily relinquished status; review contracts if your entity participated in PSO patient safety evaluations. https://www.federalregister.gov/documents/2026/07/06/2026-13604/patient-safety-organizations-voluntary-relinquishment-for-the-cassatt-patient-safety-organization
Expedited IND Pilot Program Correction: FDA corrected email contact for pilot program RFI (June 24 notice); review if your organization plans IND submissions. https://www.federalregister.gov/documents/2026/07/06/2026-13592/expedited-investigational-new-drug-pilot-program-request-for-information-correction
Multiple PRA Notices (CMS, FDA, NIH, CDC): Routine OMB clearances for information collections (home health QRP, biologics licensing, premarket medical devices, PrEP programs, cancer control surveys)—comment if collection burden affects operations.
Next Digest: July 7, 2026